Lilly posts 45% sales jump, culls four programs across obesity, Alzheimer's, heart failure and eczema

Kyle LaHucik

Senior Reporter

Eli Lilly said Thursday that its fourth-quarter revenue jumped 45% to $13.53 billion over the prior year, though this fell short of earlier projections. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly posts 45% sales jump, culls four programs across obesity, Alzheimer's, heart failure and eczema

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Bristol Myers launches fresh round of major cost cuts in bid to get ahead of patent cliff

AstraZeneca offers some detail on China probe, reaffirms commitment to that market

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

Kura's AML drug passes key study in advanced patients, plans next steps with FDA and newly diagnosed studies

Small personalized vaccine trial sees progress in late-stage kidney cancer

GSK defiant against vaccine challenges, will prioritize other growth areas

Lil­ly posts 45% sales jump, culls four pro­grams across obe­si­ty, Alzheimer's, heart fail­ure and eczema

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

Bris­tol My­ers launch­es fresh round of ma­jor cost cuts in bid to get ahead of patent cliff

As­traZeneca of­fers some de­tail on Chi­na probe, reaf­firms com­mit­ment to that mar­ket

No­vo Nordisk is feel­ing the com­pe­ti­tion from com­pound­ed GLP-1s, ex­ec says

Ku­ra's AML drug pass­es key study in ad­vanced pa­tients, plans next steps with FDA and new­ly di­ag­nosed stud­ies

Small per­son­al­ized vac­cine tri­al sees progress in late-stage kid­ney can­cer

GSK de­fi­ant against vac­cine chal­lenges, will pri­or­i­tize oth­er growth ar­eas

Lilly posts 45% sales jump, culls four programs across obesity, Alzheimer's, heart failure and eczema

Bristol Myers launches fresh round of major cost cuts in bid to get ahead of patent cliff

AstraZeneca offers some detail on China probe, reaffirms commitment to that market

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

Kura's AML drug passes key study in advanced patients, plans next steps with FDA and newly diagnosed studies

Small personalized vaccine trial sees progress in late-stage kidney cancer

GSK defiant against vaccine challenges, will prioritize other growth areas